Brief: Vaccitech Presents Interim Data From Phase 1B/2 Study Of Vtp-200 At 35Th Annual International Papillomavirus Conference (Ipvc)

Barinthus Biotherapeutics

17/04/2023 14:02

April 17 (Reuters) - Vaccitech PLC  VACC.O :
    * VACCITECH PRESENTS INTERIM DATA FROM PHASE 1B/2 STUDY OF
VTP-200
AT 35TH ANNUAL INTERNATIONAL PAPILLOMAVIRUS CONFERENCE (IPVC)
HIGHLIGHTING FAVORABLE TOLERABILITY AND IMMUNOGENICITY PROFILE
    * VACCITECH PLC - VTP-200 WAS GENERALLY WELL-TOLERATED
    * VACCITECH PLC - INTERIM DATA FROM VTP-200 SHOWED
ENCOURAGING
INITIAL IMMUNOGENICITY RESULTS, PARTICULARLY IN RELATION TO E1,
E2 AND E6 ANTIGENS

Source text for Eikon:  ID:nGNX5N8L9k 
Further company coverage:  VACC.O